Effect of Astragalus polysaccharides on expression of TNF-α, IL-1β and NFATc4 in a rat model of experimental colitis

Cytokine

Volumn 70, Issue 2, 2014, Pages 81-86

  Yang, Min ^a   Lin, Huan Bing ^b   Gong, Sitang ^a   Chen, Pei Yu ^a   Geng, Lan Lan ^a   Zeng, Yong Mei ^a   Li, Ding You ^c  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b Guangdong Food and Drug Administration Center for Evaluation and Certification   (China)

^c UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

Author keywords

Astragalus polysaccharides; Experimental colitis; IL 1 ; NFATc4; TNF

Indexed keywords

ALCOHOL; ASTRAGALUS POLYSACCHARIDE; DEXAMETHASONE; INTERLEUKIN 1BETA; MESSENGER RNA; POLYSACCHARIDE; SODIUM CHLORIDE; TRANSCRIPTION FACTOR NFAT3; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; NERVE PROTEIN; NFATC4 PROTEIN, RAT; TRANSCRIPTION FACTOR NFAT; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTRAGALUS MEMBRANACEUS; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; DRUG MEGADOSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL COLITIS; HERB; LOW DRUG DOSE; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; UPREGULATION; WEIGHT REDUCTION; ANIMAL; BODY WEIGHT; CHEMICALLY INDUCED; CHEMISTRY; COLITIS; COLON; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; ASTRAGALUS MEMBRANACEUS; BODY WEIGHT; COLITIS; COLON; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; INTERLEUKIN-1BETA; MALE; NERVE TISSUE PROTEINS; NFATC TRANSCRIPTION FACTORS; POLYSACCHARIDES; RATS, WISTAR; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84908337734     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2014.07.250     Document Type: Article

References (40)

1. Maloy K.J., Powrie F. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 2011, 474:298-306.
2. Abraham C., Cho J.H. Inflammatory bowel disease. New England J Med 2009, 361:2066-2078.
3. Xavier R.J., Podolsky D.K. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434.
4. Pedersen J., Coskun M., Soendergaard C., Salem M., Nielsen O.H. Inflammatory pathways of importance for management of inflammatory bowel disease. World J Gastroenterol: WJG 2014, 20:64-77.
5. Mustain W.C., Starr M.E., Valentino J.D., Cohen D.A., Okamura D., Wang C., et al. Inflammatory cytokine gene expression in mesenteric adipose tissue during acute experimental colitis. PLoS ONE 2013, 8:e83693.
6. Peake S.T., Bernardo D., Mann E.R., Al-Hassi H.O., Knight S.C., Hart A.L. Mechanisms of action of anti-tumor necrosis factor alpha agents in Crohn's disease. Inflamm Bowel Dis 2013, 19:1546-1555.
7. Lim W.C., Hanauer S.B. Controversies with aminosalicylates in inflammatory bowel disease. Rev Gastroenterol Dis 2004, 4:104-117.
8. Biasi F., Leonarduzzi G., Oteiza P.I., Poli G. Inflammatory bowel disease: mechanisms, redox considerations, and therapeutic targets. Antioxid Redox Signal 2013, 19:1711-1747.
9. Debnath T., Kim da H., Lim B.O. Natural products as a source of anti-inflammatory agents associated with inflammatory bowel disease. Molecules 2013, 18:7253-7270.
10. Algieri F., Rodriguez-Nogales A., Garrido-Mesa N., Zorrilla P., Burkard N., Pischel I., et al. Intestinal anti-inflammatory activity of the Serpylli herba extract in experimental models of rodent colitis. J Crohn's Colitis 2014.
11. Hur S.J., Kang S.H., Jung H.S., Kim S.C., Jeon H.S., Kim I.H., et al. Review of natural products actions on cytokines in inflammatory bowel disease. Nutr Res 2012, 32:801-816.
12. Ko J.K., Chik C.W. The protective action of radix Astragalus membranaceus against hapten-induced colitis through modulation of cytokines. Cytokine 2009, 47:85-90.
13. Mu L.X., Zhu L., Zhao A.H., Zhou M.M., Jia W. Study on extraction and purification of polysaccharides from Astragalus membranaceus. Zhong yao cai=Zhongyaocai=J Chinese Med Mater 2009, 32:1741-1745.
14. Ma X.Q., Shi Q., Duan J.A., Dong T.T., Tsim K.W. Chemical analysis of Radix Astragali (Huangqi) in China: a comparison with its adulterants and seasonal variations. J Agric Food Chem 2002, 50:4861-4866.
15. Yang M., Qian X.H., Zhao D.H., Fu S.Z. Effects of Astragalus polysaccharide on the erythroid lineage and microarray analysis in K562 cells. J Ethnopharmacol 2010, 127:242-250.
16. Minematsu H., Shin M.J., Celil Aydemir A.B., Kim K.O., Nizami S.A., Chung G.J., et al. Nuclear presence of nuclear factor of activated T cells (NFAT) c3 and c4 is required for Toll-like receptor-activated innate inflammatory response of monocytes/macrophages. Cellular Signalling 2011, 23:1785-1793.
17. Zheng L., Gao Z.Q., Wang S.X. A chronic ulcerative colitis model in rats. World J Gastroenterol: WJG 2000, 6:150-152.
18. Morris G.P., Beck P.L., Herridge M.S., Depew W.T., Szewczuk M.R., Wallace J.L. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989, 96:795-803.
19. Millar A.D., Rampton D.S., Chander C.L., Claxson A.W., Blades S., Coumbe A., et al. Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut 1996, 39:407-415.
20. Ke X., Chen J., Zhang X., Fang W., Yang C., Peng J., et al. Qing Hua Chang Yin attenuates lipopolysaccharide-induced inflammatory response in human intestinal cells by inhibiting NF-kappaB activation. Experim Therapeut Med 2013, 6:189-193.
21. Bensoussan M., Jovenin N., Garcia B., Vandromme L., Jolly D., Bouche O., et al. Complementary and alternative medicine use by patients with inflammatory bowel disease: results from a postal survey. Gastroenterol Clin Biol 2006, 30:14-23.
22. Langmead L., Rampton D.S. Review article: complementary and alternative therapies for inflammatory bowel disease. Aliment Pharmacol Ther 2006, 23:341-349.
23. Shao B.M., Xu W., Dai H., Tu P., Li Z., Gao X.M. A study on the immune receptors for polysaccharides from the roots of Astragalus membranaceus, a Chinese medicinal herb. Biochem Biophys Res Commun 2004, 320:1103-1111.
24. Wang G.L., Chen C.B., Gao J.M., Ni H., Wang T.S., Chen L. Investigation on the molecular mechanisms of anti-hepatocarcinoma herbs of traditional Chinese medicine by cell cycle microarray. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi =. China J Chinese Materia Medica 2005, 30:50-54.
25. Tian Q.E., Li H.D., Yan M., Cai H.L., Tan Q.Y., Zhang W.Y. Astragalus polysaccharides can regulate cytokine and P-glycoprotein expression in H22 tumor-bearing mice. World J Gastroenterol: WJG 2012, 18:7079-7086.
26. Zhang ZL, Chen WW. Effect of Astragalus injection in promoting IEC-6 cell differentiation through activating ornithine decarboxylase. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi=Chinese Journal of Integrated Traditional and Western Medicine/Zhongguo Zhong xi yi jie he xue hui, Zhongguo Zhong yi yan jiu yuan zhu ban, vol. 22; 2002, pp. 439-43.
27. Kim J.M. Inflammatory bowel diseases and inflammasome. Korean J Gastroenterology=Taehan Sohwagi Hakhoe chi 2011, 58:300-310.
28. Strober W., Fuss I.J. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011, 140:1756-1767.
29. Cho E.J., Shin J.S., Noh Y.S., Cho Y.W., Hong S.J., Park J.H., et al. Anti-inflammatory effects of methanol extract of Patrinia scabiosaefolia in mice with ulcerative colitis. J Ethnopharmacol 2011, 136:428-435.
30. Vivinus-Nebot M., Frin-Mathy G., Bzioueche H., Dainese R., Bernard G., Anty R., et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut 2013.
31. Yuan Y., Sun M., Li K.S. Astragalus mongholicus polysaccharide inhibits lipopolysaccharide-induced production of TNF-alpha and interleukin-8. World J Gastroenterol: WJG 2009, 15:3676-3680.
32. He X., Shu J., Xu L., Lu C., Lu A. Inhibitory effect of Astragalus polysaccharides on lipopolysaccharide-induced TNF-a and IL-1beta production in THP-1 cells. Molecules 2012, 17:3155-3164.
33. Keita A.V., Soderholm J.D. Barrier dysfunction and bacterial uptake in the follicle-associated epithelium of ileal Crohn's disease. Ann New York Acad Sci 2012, 1258:125-134.
34. Hering N.A., Fromm M., Schulzke J.D. Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. J Physiol 2012, 590:1035-1044.
35. Turner J.R. Molecular basis of epithelial barrier regulation: from basic mechanisms to clinical application. Am J Pathol 2006, 169:1901-1909.
36. Kaser A., Lee A.H., Franke A., Glickman J.N., Zeissig S., Tilg H., et al. XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease. Cell 2008, 134:743-756.
37. Simms L.A., Doecke J.D., Walsh M.D., Huang N., Fowler E.V., Radford-Smith G.L. Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease. Gut 2008, 57:903-910.
38. Wehkamp J., Salzman N.H., Porter E., Nuding S., Weichenthal M., Petras R.E., et al. Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci USA 2005, 102:18129-18134.
39. Johnstone L.S., Graham S.J., Dziadek M.A. STIM proteins: integrators of signalling pathways in development, differentiation and disease. J Cell Mol Med 2010, 14:1890-1903.
40. Wang Q., Zhou Y., Jackson L.N., Johnson S.M., Chow C.W., Evers B.M. Nuclear factor of activated T cells (NFAT) signaling regulates PTEN expression and intestinal cell differentiation. Mol Biol Cell 2011, 22:412-420.